Worldwide News

This is the latest episode of the free DDW narrated podcast, “Overcoming different barriers in drug discovery”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Addressing the challenge of salt forms in drug discovery”, “A different approach: reimagining biology”, and “Women in Discovery: championing female […]

Mitochondrial dysfunction is known to play a central role in drug-induced hepatotoxicity, and thus early detection of mitochondrial toxicity is a critical component of initial drug development efforts. While immortalised cell lines are widely used for in vitro assessment of hepatotoxicity, cryopreserved primary human hepatocytes are a preferred model for drug safety screening. Download this new […]

Biomia, the first company spun out from BioInnovation Institute’s Bio Studio programme, has secured $3 million in pre-seed financing from an international syndicate of investors. Biomia says it plans to use the investment to accelerate its development of plant-inspired natural and new-to-nature halogenated small molecule drug candidates and further build its biosynthetic manufacturing platform. Chief […]

Ginkgo Bioworks has announced a collaboration with Pfizer focused on the discovery of RNA-based drug candidates.   In the collaboration, Pfizer will leverage Ginkgo’s proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas. Ginkgo will receive an upfront payment and is eligible to receive research fees and development […]

Both GTPs and GMPs must be followed to get cell-based advanced therapies or tissue-based therapy products to market. Learn about important considerations when sourcing Leukocytes/Cellular starting materials and related ancillary products that must be factored into your programme to efficiently move through the clinical pipeline and successfully receive regulatory approval. In this webinar from BioIVT, the […]

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to 4SC’s resminostat (Kinselby) for cutaneous T-cell lymphoma (CTCL). Resminostat is an orally administered class I, IIb and IV histone deacetylase (HDAC) inhibitor that potentially offers an approach to treating different kinds of cancer. The company demonstrated that resminostat is well tolerated and can inhibit […]

The US Food and Drug Administration (FDA) has granted fast track designation to Mythic Therapeutics’ investigational cMET-targeting ADC, MYTX-011, for the treatment of patients with non-small cell lung cancer (NSCLC) with cMET overexpression. The designation for Mythic, a clinical-stage biotechnology company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of […]

The Fall issue of Drug Discovery World (DDW) is out now featuring expertise on what spatial biology tells us about drug discovery and disease. Read the digital version free here. Other features in the Fall issue include: How biomarkers can help discover new treatments for women’s health A market report on the innovation taking place across […]

The National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (DLd) for untreated multiple myeloma (MM) for routine use on the NHS in England and Wales. The therapy is now recommended within an NHS setting for the treatment of adults with newly diagnosed MM where an […]

Leucid Bio has been granted clinical trial authorisation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase I/II clinical trial evaluating autologous NKG2D-targeted CAR-T cell therapy, LEU011, in patients with relapsed or refractory solid tumours. The open-label, single patient cohort ascending dose design aims to rapidly identify the maximum tolerated […]

The European Commission (EC) has granted marketing authorisation for Jazz Pharmaceuticals’ Enrylaze as part of a multi-agent regimen for acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL). The treatment is approved in adult and paediatric patients who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. Enrylaze, approved as Rylaze in the United States and […]

Hosted by DDW and co-sponsored by Benchling and Proscia, “AI and Lab Automation: What are the key benefits and latest innovations?” will be free to attend on 10 October at 7AM PDT / 10AM EST / 3PM BST / 4PM CET. Join this free webinar to learn about the key benefits and latest innovations to […]

Umoja Biopharma has revealed data from an ongoing non-human primate (NHP) study demonstrating effective, durable, and well tolerated in vivo chimeric antigen receptor (CAR) T cell generation using the company’s VivoVec platform. The data include results from the first four NHPs treated in an ongoing study and demonstrate rapid and efficient in vivo generation of […]

This webinar supported by Thermo Fisher Scientific and presented by Generate:Biomedicines will be free to attend on 12 October 9am EDT / 2pm BST / 3pm CEST. The webinar, hosted by DDW, will feature the expertise of Adam Root, Vice President, Protein Sciences at Generate:Biomedicines who will discuss how an integrated approach of using Cryo-EM […]

Synthetic biology has shown significant potential to the drug discovery sector. Although not a new area of science, the prominence of this technology and its applications – evident during the Covid-19 pandemic – have increased of late. This has created advances in the development of new medicines and our ability to find solutions for unmet medical […]

Researchers have uncovered a link between antiviral drug molnupiravir and a pattern of mutations in the SARS-CoV-2 virus. Molnupiravir induces mutations in the virus’s genome during replication, with the aim of damaging or killing the virus. It was one of the first antivirals available on the market during the Covid-19 pandemic and was widely adopted […]